4-benzyl and 4-benzoyl-3-dimethylaminopyridin-2 (1H)-ones:: In vitro evaluation of new c-3-amino-substituted and c-5,6-alkyl-substituted analogues against clinically important HIV mutant strains

被引:28
作者
Benjahad, A
Croisy, M
Monneret, C
Bisagni, E
Mabire, D
Coupa, S
Poncelet, A
Csoka, I
Guillemont, J
Meyer, C
Andries, K
Pauwels, R
de Béthune, MP
Himmel, DM
Das, K
Arnold, E
Nguyen, CH
Grierson, DS
机构
[1] Johnson & Johnson Pharmaceut Res & Dev, Dept Med Chem, Val De Reuil, France
[2] Ctr Univ, Inst Curie, UMR 176, Lab Pharmacochim,Sect Rech,Batiment 110,CNRS, F-91405 Orsay, France
[3] Johnson & Johnson Pharmaceut Res & Dev, Virol Drug Discovery, B-2340 Beerse, Belgium
[4] TIBOTEC, B-2800 Mechelen, Belgium
[5] Ctr Adv Biotechnol & Med, Dept Biol & Chem, Piscataway, NJ 08854 USA
关键词
D O I
10.1021/jm0408621
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In a program to optimize the anti-HIV activity of the 4-benzyl and 4-benzoyl-3-dimethylaminopyridinones 9 and 10, lead compounds in a new class of highly potent non-nucleoside type inhibitors of HIV-1 reverse transcriptase, modification of the alkyl substitutents at the C-5 and C-6 positions on the pyridinone ring and of the substitutents on the C-3 amino group has been studied. Of the 17 new 5/6-modified analogues prepared, compounds 31b and 32b substituted at C-5 by an extended nonpolar chain containing an ether function and a C-6 methyl group and compound 35 bearing a C-5 ethyl/C-6 hydroxymethyl substituent pattern were selected on the basis of their in vitro activity against wild-type HIV and the three principle mutant strains, K103N, Y181C, and Y188L. When tested further, it was shown that these molecules, and in particular compound 35, are globally more active than 9, 10, and efavirenz against an additional eight single [L100I, K101E, V106A, E138K, V179E, G190A/S, and F227C] and four double HIV mutant strains [L1001 + K103N, K101E + K103N, K103N + Y181C, and F227L + V106A] which are clinically relevant. Concerning modulation of the N-3 substituent, 36 new analogues were prepared. Of these, the N-methyl-N-(2-methoxyethyl)-substituted compounds 40, 42, and 62, as well as the doubly modified compounds 77a and 77b, were selected from the initial screen and were subsequently shown to be active at sub-micromolar concentrations (IC50'S) against all the other mutant strains except K103N + Y181C and F227L + V106A. Two possible, but distinct, modes of binding of these analogues in RT were suggested from molecular modeling studies. The preferred mode of binding for compound 62, corresponding to the predicted "orientation 1", was revealed in the X-ray crystal structure of the compound 62-RT complex.
引用
收藏
页码:1948 / 1964
页数:17
相关论文
共 43 条
[1]  
ANDREOLA ML, 1997, Patent No. 9705113
[2]   Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance [J].
Bastard, JP ;
Caron, M ;
Vidal, H ;
Jan, V ;
Auclair, M ;
Vigouroux, C ;
Luboinski, J ;
Laville, M ;
Malachi, M ;
Girard, PM ;
Rozenbaum, W ;
Levan, P ;
Capeau, J .
LANCET, 2002, 359 (9311) :1026-1031
[3]   4-Benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents:: Optimization and in vitro evaluation against clinically important HIV mutant strains [J].
Benjahad, A ;
Courté, K ;
Guillemont, J ;
Mabire, D ;
Coupa, S ;
Poncelet, A ;
Csoka, I ;
Andries, K ;
Pauwels, R ;
de Béthune, MP ;
Monneret, C ;
Bisagni, E ;
Nguyen, CH ;
Grierson, DS .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (22) :5501-5514
[4]   Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study [J].
Carr, A ;
Samaras, K ;
Thorisdottir, A ;
Kaufmann, GR ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1999, 353 (9170) :2093-2099
[5]   Adverse effects of antiretroviral therapy [J].
Carr, A ;
Cooper, DA .
LANCET, 2000, 356 (9239) :1423-1430
[6]   Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant [J].
Das, K ;
Ding, JP ;
Hsiou, Y ;
Clark, AD ;
Moereels, H ;
Koymans, L ;
Andries, K ;
Pauwels, R ;
Janssen, PAJ ;
Boyer, PL ;
Clark, P ;
Smith, RH ;
Smith, MBK ;
Michejda, CJ ;
Hughes, SH ;
Arnold, E .
JOURNAL OF MOLECULAR BIOLOGY, 1996, 264 (05) :1085-1100
[7]   Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants [J].
Das, K ;
Clark, AD ;
Lewi, PJ ;
Heeres, J ;
de Jonge, MR ;
Koymans, LMH ;
Vinkers, HM ;
Daeyaert, F ;
Ludovici, DW ;
Kukla, MJ ;
De Corte, B ;
Kavash, RW ;
Ho, CY ;
Ye, H ;
Lichtenstein, MA ;
Andries, K ;
Pauwels, R ;
de Béthune, MP ;
Boyer, PL ;
Clark, P ;
Hughes, SH ;
Janssen, PAJ ;
Arnold, E .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (10) :2550-2560
[8]   New developments in anti-HIV chemotherapy [J].
De Clercq, E .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2002, 1587 (2-3) :258-275
[9]  
DING J, 1997, STRUCTURE BASED DRUG, P41
[10]   Synthesis and antiviral activity of 4-benzyl pyridinone derivatives as potent and selective non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors [J].
Dollé, V ;
Nguyen, CH ;
Legraverend, M ;
Aubertin, AM ;
Kirn, A ;
Andreola, ML ;
Ventura, M ;
Tarrago-Litvak, L ;
Bisagni, E .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (21) :3949-3962